Director of Supply Chain and Warehouse Operations

OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Join Us in Changing Lives At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. Following the expansion of our US footprint with the acquisition of a new commercial-scale viral vector facility in Durham, North Carolina we have some new opportunities to join us. We are recruiting a Director, Supply Chain & Warehouse Operations to join the Durham Leadership Team. In this role, you will lead end-to-end supply chain and warehouse operations, ensure reliable supply, and support site growth—playing a key role in advancing our mission and making a meaningful impact. Your responsibilities in this role would be:

• Lead end-to-end supply chain and warehouse operations to ensure seamless procurement, planning, inventory management, and logistics across the site.
• Own and deliver effective supply planning and S&OP execution, aligning material availability with production schedules and business demand.
• Ensure uninterrupted material supply to support Manufacturing, MSAT, Quality, and R&D, safeguarding operational continuity.
• Develop and optimise inventory and supplier strategies to balance cost, risk, service levels, and working capital performance.
• Drive supply chain excellence and compliance, enhancing processes, systems, and governance in line with cGMP and regulatory requirements.
• Build and lead a high-performing team while partnering cross-functionally to support technical transfers, scale-up, and future site growth.

We are looking for:

• A Bachelor’s degree in Supply Chain, Business, Operations Management, Engineering, Life Sciences, or a related field is required.
• Significant leadership experience (10+ years in supply chain, including leading teams within cGMP manufacturing environments).
• Proven end-to-end supply chain expertise, spanning procurement, planning, inventory, warehousing, logistics, and supplier management.
• Strong knowledge of cGMP and regulated environments, with experience ensuring compliance and supporting manufacturing operations.
• Demonstrated leadership and team development capability, with a track record of building high-performing teams in fast-paced, evolving settings, Commercial and analytical acumen, including budgeting, cost control, inventory optimisation, and data-driven decision-making.
• Experience in advanced or complex manufacturing settings (e.g., biologics, cell & gene therapy, CDMO), with exposure to technical transfer, scale-up, or supply chain transformation initiatives

This role does not offer sponsorship for work authorization. External applicants must be eligible to work in the United States. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why Join Us? 💸 Competitive total reward packages 🧘 Wellbeing programs that support your mental and physical health 🚀 Career development opportunities to help you grow and thrive 🤝 Supportive, inclusive, and collaborative culture 🧪 State-of-the-art labs and manufacturing facilities 🌍 A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.